Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
ImmuneWalk Therapeutics has presented positive topline data from the single ascending dose (SAD) part of the randomised, first-in-human Phase I …
While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a …
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at …
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA) at …
Against the backdrop of the recent US Food and Drug Administration’s (FDA) staff cuts and administrative realignment, understanding accelerated approval …
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV …
The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current …
MSD's Enflonsia (clesrovimab) has received FDA approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) …
German biopharmaceutical company HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver …
US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for …
On January 6, 2025, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) issued its …
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical …
As of April 2025, GlobalData’s Drugs database shows 8,684 investigative drugs under active development by emerging pharmaceutical companies, which are …